Pseudoxanthoma Elasticum (PXE)
Pseudoxanthoma elasticum (PXE) is an autosomal recessive, multisystem genetic disorder in which the elastic fibers of the extracellular matrix progressively calcify and fragment. At the molecular level, PXE is caused by inactivating mutations in both copies of the ABCC6 gene (on chromosome 16p13.11). This gene encodes MRP6 (multidrug resistance-associated protein 6), a transmembrane transporter found mainly in the liver and kidneys. When MRP6 does not work, cells release less ATP into the circulation, and blood levels of inorganic pyrophosphate (PPi), a key natural inhibitor of misplaced mineralization, fall sharply. Calcium and phosphate then deposit spontaneously as hydroxyapatite crystals, damaging elastic-fiber-rich tissues such as the skin, Bruch's membrane in the eye and the middle layer (media) of medium-sized arteries.
At Haute-Derma, we see PXE not as a purely cosmetic skin problem but as an early clinical marker of a serious systemic disease. Because the skin is often the first organ to show changes, our clinic acts as a key screening point: we confirm the diagnosis under the microscope and coordinate with other specialists to protect patients from vision loss and vascular events.
Our Specialist Approach to Managing Pseudoxanthoma Elasticum (PXE)
Because PXE severely damages the mid-dermis, our protocol at Haute-Derma follows these clinical principles closely:
- Slowing and managing microscopic mineralization: medical and dietary measures aim to optimize the body's PPi-to-calcium balance and slow the deposition of new crystals onto healthy elastic fibers.
- Avoiding aggressive resurfacing or extensive skin-tightening surgery: PXE skin has lost its natural elasticity and become lax because its elastic fibers are broken. Standard excision of excess skin or conventional facelifts carry a high risk of poor results, slow healing and unsightly scars, because the dermis cannot provide enough support.
- Mandatory vascular and retinal screening: every patient with skin findings suggestive of PXE is enrolled in regular eye (fundus) examinations and circulatory assessments to catch hidden vascular damage early.
Screening and Microscopic Diagnosis of PXE at Haute-Derma
To establish a firm diagnosis of PXE, Haute-Derma follows a standard workup of laboratory and tissue tests:
- Dermatological mapping: we look for small yellow papules (1–5 mm) that merge into net-like (reticular) plaques in skin folds such as the neck, armpits and groin, giving the classic "plucked chicken skin" appearance, along with loose skin that has lost its ability to spring back.
- Skin biopsy and special stains: a punch biopsy is taken from an affected area down to the dermis. The tissue is processed with a von Kossa stain (which turns calcium deposits black) or a Verhoeff–Van Gieson (VVG) stain (which highlights elastic fibers that are distorted, swollen, clumped and broken into small fragments). This is the gold standard for the histological diagnosis of PXE.
- Fundus examination and fluorescein angiography: these look for angioid streaks, cracks in a calcified Bruch's membrane that set the stage for choroidal neovascularization (CNV) and retinal bleeding.
- Genetic testing: next-generation sequencing of the ABCC6 gene confirms the diagnosis at the molecular level and supports genetic counseling for the family.
Treatment and Tissue Support at Haute-Derma
Although there is no curative gene therapy yet, our PXE management at Haute-Derma focuses on preserving tissue structure and easing cosmetic concerns:
- Non-ablative fractional laser (1550 nm): unlike more invasive procedures, this laser creates microscopic columns of heat that reach the dermis without breaking the skin surface. This stimulates a healthy new collagen framework around them and firms up loose, sagging skin on the neck and in the armpits.
- Supportive medical therapy to limit calcification: together with internal medicine specialists, we advise on magnesium supplementation (magnesium competes with and inhibits calcium phosphate crystal formation) and careful control of calcium intake, keeping it at normal physiological levels and avoiding high-dose calcium supplements.
- Working with ophthalmologists to prevent vision loss: for patients who already have angioid streaks, we arrange referral for intravitreal injections of anti-VEGF agents such as ranibizumab or aflibercept to close off leaking new vessels and preserve central vision.
